Holen Sie sich die Stockscreener-App
0.2177
3.76%
0.0076
Handel nachbörslich:
.23
0.0123
+5.65%
Schlusskurs vom Vortag:
$0.2101
Offen:
$0.219
24-Stunden-Volumen:
12.69M
Relative Volume:
0.74
Marktkapitalisierung:
$51.03M
Einnahmen:
$48.47M
Nettoeinkommen (Verlust:
$-170.37M
KGV:
-0.2903
EPS:
-0.7499
Netto-Cashflow:
$-171.35M
1W Leistung:
+9.49%
1M Leistung:
-39.90%
6M Leistung:
-93.47%
1J Leistung:
-81.83%
1-Tages-Spanne:
$0.2112
$0.2388
1-Wochen-Bereich:
$0.19
$0.24
52-Wochen-Spanne:
$0.1626
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Firmenname
Gossamer Bio Inc
Sektor
Branche
Telefon
(858) 684-1300
Adresse
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.2175 | 49.31M | 48.47M | -170.37M | -171.35M | -0.7499 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-02-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2025-07-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-05 | Fortgesetzt | Wedbush | Outperform |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-03-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Eingeleitet | Guggenheim | Neutral |
| 2022-12-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Neutral |
| 2022-09-19 | Eingeleitet | Wedbush | Outperform |
| 2022-04-18 | Eingeleitet | Raymond James | Outperform |
| 2022-04-06 | Eingeleitet | UBS | Buy |
| 2022-01-10 | Hochstufung | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-30 | Eingeleitet | Berenberg | Buy |
| 2019-03-05 | Eingeleitet | Barclays | Overweight |
| 2019-03-05 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-05 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-05 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Portnoy Law Firm Announces Class Action on Behalf of Gossamer Bio, Inc. Investors - GlobeNewswire
GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities LawsuitContact The Gross Law Firm - PR Newswire
GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS – Company AnnouncementFT.com - Financial Times
GOSS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
GOSS Stockholders Have Opportunity to Lead Gossamer Bio, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
GOSSAMER DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Gossamer Bio, Inc. ... - Caledonian Record
GOSSAMER DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW - GlobeNewswire
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile
GOSS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS - PR Newswire
GOSS 10-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses Ma - The National Law Review
GOSS Investor AlertGossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - PR Newswire
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
GOSS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile
GOSSAMER DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile
Earnings call transcript: Gossamer Bio Q1 2026 sees revenue beat, EPS miss - Investing.com UK
Gossamer Bio, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:GOSS) 2026-05-21 - Seeking Alpha
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
GOSSAMER BIO, INC. (GOSS) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by June 1, 2026 - marketscreener.com
GOSS Investor Alert: Gossamer Bio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Concealing Placebo Response Risks: SueWallSt - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile
Goldman Sachs Adjusts Outlook for Gossamer Bio (GOSS) - GuruFocus
Robbins LLP Reminds GOSS Investors of the Pending Class - GlobeNewswire
Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2026 Earnings Call Transcript - Insider Monkey
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile
Wedbush Maintains Gossamer Bio(GOSS.US) With Hold Rating, Maintains Target Price $1 - Moomoo
GOSS Maintained by Barclays -- Price Target Lowered to $0.28 - GuruFocus
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action - GlobeNewswire
The Gross Law Firm Reminds Gossamer Bio, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 1, 2026GOSS - Morningstar
Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - Sahm
Is Gossamer Bio (GOSS) Undervalued After Q1 2026? EPS -$0.20 (mi - GuruFocus
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit - GuruFocus
Gossamer Bio (GOSS) Reports Mixed Results for PROSERA in Q1 2026 Earnings Call - GuruFocus
Key facts: Gossamer Bio voting deals; PROSERA benefit; Q1 loss $46.7M - TradingView
GOSS Stock Chart | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
GOSS Reports $99.2 Million in Cash Reserves for Future Operations - GuruFocus
Gossamer Bio Q1 Net Loss Expands; Eyes On The Pre-NDA Meeting With FDA For Seralutinib W In Mid-June - RTTNews
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel ... - Caledonian Record
Latham Represents Gossamer Bio Inc in Exchange Offer and Consent Solicitation Transaction - Latham & Watkins LLP
Gossamer targets September 2026 seralutinib NDA filing with potential Q3 2027 approval - MSN
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bi - GuruFocus
Gossamer Bio Q1 2026 Deep Dive: EPS Misses by 17.6%, Revenue Up 72% - AlphaStreet
GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses M - GuruFocus
Gossamer Bio shares decline after wider-than-expected Q1 loss despite revenue beat (GOSS) - MSN
Gossamer Bio Q1 2026 Earnings Call Transcript - MarketBeat
Finanzdaten der Gossamer Bio Inc-Aktie (GOSS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):